A Multicenter, Open-Label, Phase II Study of LE-DT for Efficacy and Safety in Patients With Metastatic Castrate Resistant Prostate Cancer.
Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 14 Mar 2018
At a glance
- Drugs Docetaxel (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- Sponsors INSYS Therapeutics, Inc
- 12 Mar 2018 Status changed to withdrawn prior to enrolment.
- 10 Jun 2017 Biomarkers information updated
- 06 Sep 2010 New trial record